<DOC>
	<DOCNO>NCT00676221</DOCNO>
	<brief_summary>Hypothesis : Presently , patient ' mycophenolate mofetil ( MMF. , Cellcept ) relate gastrointestinal ( GI ) symptoms spontaneously report . It postulate conversion enteric-coated mycophenolate sodium ( EC-MPS. , Myfortic ) MMF reduce objectively measure GI symptom burden improve GI-related quality life . Primary Objective : To determine incidence GI-related symptom health relate quality life renal transplant patient currently tolerate MMF . Assessed GSRS GIQLI . Secondary Objective : To determine impact GI symptoms health relate quality life renal transplant patient convert MMF Myfortic . Assessed GSRS GIQLI .</brief_summary>
	<brief_title>Patient Reported Outcomes Renal Transplant Patients Tolerating Gastrointestinal ( GI ) Symptoms Converted Myfortic ( EC-MPS )</brief_title>
	<detailed_description>Investigator originate proposal . Single centre-Foothills Medical Centre , Southern Alberta Transplant Program . Study design : Three month , longitudinal , open-label , single arm study . Number study visit : 3 ( Baseline , 4-6 week , 12 week ) Planned sample size : Approx . 110 subject . Study population primary secondary renal transplant recipient stable maintenance immunosuppressive medication include MMF . Gastrointestinal rating scale ( GSRS ) Gastrointestinal Quality Life Index ( GIQLI ) evaluation tool GI symptom , complete study subject via `` touch screen '' pc . baseline , 4-6 week final 12 week visit . Study subject discontinue MMF follow even dose day Baseline visit commence EC-MPS equimolar dos subject 's current MMF dose . At Final study visit ( Week 12 ) study subject give option continue EC-MPS resume MMF . Endpoints : Primary : Incidence patient tolerate MMF related GI symptom . Secondary : 1 . Patient report symptom quality life conversion MMF EC-MPS . 2 . Adverse event . 3 . Renal function determine Cockroft-Gault equation 4 . Routine hematological chemistry bloodwork . Statistical consideration : Descriptive , pair T-Test analysis .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Stable primary secondary renal transplant recipient , male female . 1875 year age . Stable GFR ( &gt; 30ml/min ) CockroftGault equation time last clinic visit Screening/Baseline visit . Immunosuppression drug regimen include MMF ( Cellcept ) least 4 week prior study enrollment . Renal transplant recipient tolerate willing tolerate GI symptom related MMF . Patients willing capable give write informed consent study participation . Nonstable renal transplant recipient ( infection , thrombocytopenia , neutropenia , anemia , fluctuate GFR , acute rejection &lt; 1 week prior study enrollment etc . ) Malignancies treat basal cell squamous cell carcinoma skin . Other serious medical condition ( uncontrolled diabetes , peptic ulcer , etc ) GI symptom relate MMF ( ie infectious diarrhoea ) Women childbearing potential unwilling use effective mean contraception . Presence psychiatric illness would interfere study requ1rements . Ongoing acute medical intervention hospitalization . Patients receive investigational drug receive investigational drug within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Renal transplant recipient</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Gastro-intestinal symptom</keyword>
	<keyword>Quality life</keyword>
	<keyword>Cellcept</keyword>
	<keyword>Myfortic</keyword>
	<keyword>Kidney transplant patient .</keyword>
</DOC>